Birth
Introduction
Birth, also known as parturition, is the physiological process by which a fetus is expelled from the uterus, marking the end of gestation and the beginning of independent life. It is a complex and highly regulated event crucial for the continuation of species.
Biological Basis
The biological process of birth involves a coordinated cascade of hormonal signals and physical changes. Key hormones like oxytocin and prostaglandins play a central role in initiating and sustaining uterine contractions, leading to cervical dilation and the eventual expulsion of the baby. The timing and progression of birth are influenced by a combination of maternal, fetal, and placental factors. Genetic predispositions in both the mother and the fetus are understood to contribute to variations in gestational length, labor onset, and birth outcomes.
Clinical Relevance
The circumstances surrounding birth, particularly factors such as gestational age and birth weight, are clinically significant predictors of an individual's long-term health. Low birth weight and preterm birth are associated with increased risks for various health issues later in life, including cardiovascular disease (CVD) and type 2 diabetes (T2D). [1] Research from birth cohorts, such as the Northern Finland Birth Cohort (NFBC1966) and the Helsinki Birth Cohort study, has demonstrated associations between early life factors and adult health outcomes, including blood pressure at age 31 [2] trajectories of growth and coronary events in adulthood [3] low-grade inflammation in young adulthood [4] and serum lipid levels 60 years later. [5] These studies highlight the importance of understanding the genetic and environmental factors influencing birth and early growth for preventive healthcare strategies. [6]
Social Importance
From a societal perspective, birth is a fundamental public health concern. Ensuring healthy birth outcomes is a global priority, impacting population health, economic stability, and societal well-being. Public health initiatives often focus on reducing rates of preterm birth and low birth weight, improving maternal and infant mortality rates, and supporting healthy early childhood development. The social and cultural significance of birth is profound, often marked by rituals and traditions that reflect its central role in human experience.
Methodological and Statistical Constraints
Genetic studies often face challenges in statistical power due to sample size limitations, which can hinder the detection of modest genetic effects. For example, some analyses have been conducted with fewer than 1,000 participants for certain phenotypes, significantly reducing the ability to identify variants that explain less than 4% of the phenotypic variation, even with stringent significance levels. [7] This constraint increases the risk of false-negative findings for genetic variants that may have smaller, yet clinically meaningful, contributions. [8] The stringency of genome-wide significance thresholds, while necessary to control for multiple testing, further exacerbates this challenge, meaning many potentially relevant associations may not reach statistical significance and remain hypothesis-generating, necessitating further replication. [7]
The reliability of identified associations is also impacted by the need for robust replication in independent cohorts, as moderate initial findings may sometimes represent false positives. [7] Studies can encounter difficulties replicating previously reported findings due to factors like partial coverage of genetic variation by genotyping arrays or reliance on proxy SNPs with less-than-perfect linkage disequilibrium during imputation. [1] Furthermore, effect size estimates can be inflated if derived from discovery cohorts or selectively chosen replication samples, potentially overstating the true genetic contribution of a variant to the trait. [9] Different analytical methods, such as GEE-based versus FBAT-based analyses, can also yield non-overlapping top signals, highlighting the interpretive challenges arising from methodological differences. [7]
Phenotypic Definition and Measurement Variability
Accurately defining and measuring complex traits is a critical hurdle in genetic research. When phenotypes are averaged over extended periods, spanning decades or involving different measurement equipment, it can introduce misclassification and mask age-dependent genetic effects. [7] Such averaging implicitly assumes that the same genetic and environmental factors influence the trait consistently across a wide age range, an assumption that may not always hold true. [7] This variability in phenotypic characterization can obscure genuine genetic associations or lead to spurious findings, making it difficult to precisely link genetic variants to specific aspects of the trait.
Beyond the challenges of long-term phenotypic assessment, immediate environmental or physiological factors can also influence trait measurements. For instance, the time of day when samples are collected or the menopausal status of participants can significantly affect biochemical markers, and if these variables are not consistently controlled, they can confound genetic association analyses. [10] Moreover, the completeness of genetic data is dependent on the genotyping platforms used, with some arrays providing only partial coverage of genetic variation, which can limit the ability to identify or replicate associations for certain candidate genes. [7] When direct genotyping is not possible, relying on imputed genotypes or proxy SNPs, even with high linkage disequilibrium, introduces a degree of uncertainty that can affect the precision and interpretation of association signals. [1]
Generalizability and Unaccounted Factors
A significant limitation in many genetic studies is the generalizability of findings, particularly when research is conducted primarily in specific populations, such as those of European descent or from founder populations. [11] While these studies provide valuable insights into genetic architecture within those groups, their results may not be directly transferable to individuals of other ancestries due to differences in allele frequencies, genetic architecture, and environmental exposures. [7] Additionally, the use of specialized cohorts, such as twin registries or volunteer samples, can introduce selection biases that may not fully reflect the genetic and phenotypic diversity of the broader general population. [10]
Despite evidence of heritability for many complex traits, a considerable portion of the genetic variance often remains unexplained by identified common variants, a phenomenon known as "missing heritability". [10] This suggests that other genetic factors, such as rare variants, structural variations, or complex epistatic interactions, which are typically beyond the scope of standard genome-wide association studies, may play a substantial role. [7] Furthermore, genetic variants often influence phenotypes in a context-dependent manner, with their effects being modulated by environmental factors. [7] The lack of comprehensive investigation into these gene-environment interactions represents a significant gap in current knowledge, as it means that the full impact of genetic predisposition may not be accurately captured without considering the intricate interplay with environmental exposures. [1]
Variants
Genetic variations play a crucial role in shaping human development and health, with numerous single nucleotide polymorphisms (SNPs) influencing gene function and contributing to complex traits, including those relevant to birth outcomes. Variants within genes like CKAP2L, RNASET2, and SMAD9 are implicated in fundamental biological processes essential for early life. For instance, CKAP2L (Cytoskeleton Associated Protein 2 Like) is vital for proper cell division, particularly during mitosis, ensuring accurate chromosome segregation. A variant such as rs7594852 could potentially disrupt this intricate process, leading to errors in cell proliferation critical for embryonic and fetal development, which might manifest as developmental abnormalities or growth restrictions at birth . Similarly, RNASET2 encodes a ribonuclease essential for RNA degradation and metabolism, processes fundamental to cellular health and differentiation. The rs3777722 variant might alter this enzyme's activity, potentially affecting RNA processing pathways that are vital for neurodevelopment, with implications for neurological conditions observed from birth . Meanwhile, SMAD9 is a key component of the BMP signaling pathway, which orchestrates embryonic development, tissue differentiation, and bone formation. The rs563538 variant could modify SMAD9's signaling capacity, potentially leading to congenital malformations, skeletal dysplasias, or cardiovascular defects present at birth due to impaired developmental cues .
Other variants, including those near ADGRL2, EMX2, and RND3, are associated with processes critical for the nervous system and overall structural development. ADGRL2 (Adhesion G Protein-Coupled Receptor L2) is involved in crucial cell adhesion and signaling events, particularly in neuronal development and synapse formation. The rs480745 variant, located in proximity to ADGRL2 and LINC01362, might influence the precision of neuronal connections or the regulatory landscape of gene expression, thereby affecting brain development and potentially contributing to neurodevelopmental disorders or structural brain anomalies detectable at birth . EMX2 (Empty Spiracles Homeobox 2) is a transcription factor pivotal for the formation of the central nervous system, including the cerebral cortex, and the urogenital system. Variants like rs7077608 can significantly impact EMX2 expression or function, leading to severe congenital malformations such as schizencephaly or renal agenesis, which are serious birth defects . Furthermore, RND3 (Rho Family GTPase 3) plays a critical role in regulating the actin cytoskeleton, cell migration, and adhesion, which are fundamental for morphogenesis and tissue organization during embryogenesis. The rs12474944 variant, located near LINC01818, could affect RND3 activity, potentially leading to congenital defects by disrupting the precise cellular movements and structural organization required for proper organ formation .
Finally, variants in genes like SORL1, MAN1A1, IRF8, and SLC29A3 influence diverse cellular functions with potential implications for birth and early development. SORL1 (Sortilin Related Receptor 1) is a trafficking receptor involved in neuronal function and lipid metabolism, and while primarily studied in adult conditions, its role in brain development suggests that rs10892761 could influence early brain architecture or metabolic pathways crucial for fetal growth . MAN1A1 (Mannosidase Alpha Class 1A Member 1) is an enzyme critical for protein glycosylation, a process essential for protein folding and function. A variant such as rs2794256 could impair glycosylation, leading to congenital disorders of glycosylation (CDG) that manifest with severe multi-systemic issues at birth, affecting neurological, skeletal, and organ development . IRF8 (Interferon Regulatory Factor 8) is a transcription factor vital for immune cell development and function, influencing susceptibility to infections. The rs305080 variant might alter immune responses, potentially impacting fetal health and susceptibility to perinatal infections or immune dysregulation in the newborn . Lastly, SLC29A3 (Solute Carrier Family 29 Member 3) encodes a nucleoside transporter crucial for DNA/RNA synthesis and energy metabolism. Variants like rs780676 can impair nucleoside transport, leading to rare syndromes characterized by severe developmental abnormalities, immunodeficiency, and neurological problems evident at birth or early in life, highlighting the fundamental role of these transporters in rapid cellular growth .
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs7594852 | CKAP2L | birth measurement gestational age |
| rs3777722 | RNASET2 | birth measurement |
| rs480745 | ADGRL2 - LINC01362 | birth measurement |
| rs563538 | SMAD9 | birth measurement |
| rs10892761 | SORL1 | birth measurement bitter alcoholic beverage consumption measurement |
| rs2794256 | MAN1A1 - MIR3144 | birth measurement |
| rs12474944 | LINC01818 - RND3 | birth measurement |
| rs7077608 | EMX2 - LINC02674 | birth measurement |
| rs305080 | IRF8 | birth measurement |
| rs780676 | SLC29A3 | birth measurement |
Conceptual Frameworks of Birth and Early Life Traits
In genetic and epidemiological research, 'birth' serves as a foundational reference point, particularly in the context of "birth cohort" studies, which track individuals born within a specific timeframe to investigate long-term health trajectories . Variability in these measures, such as "low birth weight," represents a significant clinical phenotype, indicating potential risks and requiring further attention. [6] These initial measurements provide a baseline for assessing an individual's developmental trajectory.
Measurement approaches for these characteristics are standardized to ensure accuracy and comparability across studies. Height and body weight are typically obtained using a standardized height measure and a calibrated scale. [12] BMI is then derived by calculating kilograms per square meter (kg m−2). [12] To account for natural variations, statistical methods often involve generating normalized residuals, which can be further adjusted for factors like age and sex, to better analyze individual differences and their clinical significance in research settings . [13], [14], [15], [16]
Longitudinal Growth Patterns and Phenotypic Diversity
Following birth, the assessment of early growth patterns and trajectories is crucial for understanding an individual's development and identifying phenotypic diversity. Clinical presentations include the observation of "trajectories of growth among children" and "growth before 2 years of age," which are dynamic indicators of health . [3], [5] These patterns exhibit significant inter-individual variation, contributing to a broad spectrum of phenotypic diversity, which researchers often categorize to identify "groups at risk" based on deviations from typical growth. [6]
Measurement approaches for longitudinal growth involve repeated anthropometric assessments over time. These serial measurements are then used to model growth trajectories. In research, continuous covariates such as a subject’s birth BMI and early growth are often incorporated into linear regression models to evaluate their additive genetic effects and interactions with other factors. [12] To enhance diagnostic significance and reduce confounding, these growth phenotypes are frequently analyzed as age-sex adjusted or multivariable adjusted residuals, accounting for expected variations and isolating specific influences . [14], [15], [16]
Clinical Significance and Predictive Value
The characteristics observed at birth and during early growth hold substantial diagnostic and prognostic significance, serving as crucial indicators for future health outcomes. Early life factors, including size at birth and growth before two years of age, have been directly correlated with adult health conditions such as blood pressure at age 31 years and serum lipid profiles 60 years later . [2], [5] These correlations highlight the long-term predictive value of initial anthropometric data.
Furthermore, birth characteristics are significant prognostic indicators for metabolic and inflammatory states in young adulthood. For instance, an individual's size at birth and subsequent weight gain over the life course have been linked to low-grade inflammation in young adulthood. [4] Such findings underscore the importance of monitoring birth parameters and early growth as red flags for later-life disease risk, allowing for potential early interventions or targeted health management strategies based on these foundational clinical correlations.
Genetic Influences on Birth Characteristics
Birth characteristics, such as size at birth, are significantly influenced by an individual's genetic makeup. Genome-wide association studies (GWAS) conducted in birth cohorts have identified numerous genetic variations associated with metabolic traits and other quantitative phenotypes measured at birth or in early life. [1] These inherited variants often contribute to a polygenic risk profile, where many genes with small effects collectively determine a predisposition to certain birth-related traits or subsequent health outcomes. [17] Furthermore, the heritability of quantitative traits, including those related to birth, has been estimated, demonstrating a clear genetic component. [18]
The genetic landscape of birth cohorts can also be shaped by population structure, particularly in founder populations or isolates, where patterns of genetic similarity between individuals correlate with their population of origin . [1], [19], [20], [21] This population-specific genetic architecture, characterized by distinct linkage disequilibrium patterns, plays a role in identifying genetic signals related to birth characteristics and disease predisposition . [1], [19] While Mendelian forms are not explicitly detailed for 'birth' itself, the context does mention specific genetic loci influencing conditions like fetal hemoglobin production, which could indirectly relate to aspects of birth health, such as the BCL11A gene . [22], [23]
Maternal and Environmental Determinants
The environment surrounding birth, particularly the maternal prenatal environment, significantly impacts birth characteristics. Factors such as maternal lifestyle, diet, and exposures during pregnancy contribute to variations in fetal growth and subsequent health trajectories . [2], [4] For instance, early life factors are known to influence various physiological measures in adulthood, underscoring the long-lasting effects of the prenatal and immediate postnatal environment. [2] Low birth weight, a critical birth characteristic, is associated with specific risk groups, indicating environmental and maternal health influences. [6]
Beyond direct maternal physiological factors, broader environmental and socioeconomic conditions can also shape birth outcomes. Geographic influences, often reflected in the "population of origin," can correlate with observed genetic similarities and potentially environmental exposures that impact birth characteristics. [1] While specific socioeconomic factors are not explicitly detailed, the existence of birth cohorts across diverse populations suggests an acknowledgment of varying environmental contexts influencing early life development and health. [24] Early growth patterns, influenced by both biological and environmental factors, are shown to have profound implications for metabolic health decades later. [5]
Gene-Environment Interplay and Developmental Trajectories
The characteristics observed at birth and their subsequent health implications are not solely determined by genetics or environment in isolation, but by their complex interplay. Research actively investigates gene-environment interactions, where the effect of specific genetic loci on traits can be modified by environmental factors or continuous covariates like birth BMI and early growth. [1] For example, specific gene-by-environment testing has been conducted for SNPs associated with traits like uric acid concentration, such as rs16890979 in SLC2A9, rs2231142 in ABCG2, and *rs1165205_ in SLC17A3, demonstrating how genetic predispositions interact with various environmental factors to influence health outcomes. [11] This highlights that genetic risk often manifests differently depending on the environmental context experienced from conception onward.
Early life influences, particularly fetal growth and subsequent growth patterns, are critical determinants of long-term health, acting as a developmental trajectory initiated at birth. There is a recognized relationship between fetal growth and the risk for chronic diseases such as cardiovascular disease (CVD) and type 2 diabetes (T2D) in adulthood. [1] Studies have consistently shown that factors like size at birth, weight gain during childhood, and overall growth before two years of age are strongly associated with metabolic traits and health markers decades later, including blood pressure, serum lipids, and inflammation levels . [2], [4], [5] These developmental factors, shaped by both genetic and environmental inputs, establish a foundation for an individual's health trajectory.
Early Life Development and Metabolic Trajectories
Birth represents a critical developmental milestone, with early life factors significantly influencing an individual's long-term health trajectory. Fetal growth and gestational age are fundamental aspects of this period, directly impacting an individual's size at birth. [12] Deviations in these early developmental processes, such as specific patterns of growth during childhood, have been linked to an increased risk for various chronic conditions in adulthood, including cardiovascular disease (CVD) and type 2 diabetes (T2D). [3] Studies indicate that early growth patterns, even before two years of age, can predict serum lipid levels six decades later, highlighting the profound and lasting impact of early development on systemic metabolic homeostasis. [5] Furthermore, the interplay between size at birth and weight gain throughout life can contribute to the development of low-grade inflammation in young adulthood, underscoring the complex, interconnected nature of developmental and metabolic processes. [4]
Genetic Regulation of Development and Metabolism
Genetic mechanisms play a pivotal role in shaping both early life development and subsequent metabolic health. Genome-wide association studies (GWAS) are employed to identify specific genetic variants that influence birth-related traits and metabolic profiles. [12] For instance, a quantitative trait locus (QTL) influencing fetal hemoglobin (F cell) production has been mapped to a gene encoding a zinc-finger protein on chromosome 2p15, with BCL11A identified as a key nuclear and repressor protein involved in this process. [22] Such genetic variations can impact the homeostasis of critical biomolecules like lipids, carbohydrates, and amino acids, thereby influencing an individual's physiological state. [25] Beyond individual gene effects, regulatory elements and epigenetic modifications can influence gene expression patterns during development, potentially programming an individual for specific metabolic outcomes later in life.
Molecular Pathways and Biomarkers of Early Life Health
The physiological state at birth and its long-term consequences are reflected through various molecular and cellular pathways, identifiable by key biomolecules. Metabolic parameters such as insulin (INS), glucose (GLU), C-reactive protein (CRP), total cholesterol (TC), high-density lipoprotein (HDL), and triglycerides (TG) are routinely measured to assess metabolic health. [12] These biomolecules are integral to fundamental metabolic processes, including energy regulation, lipid transport, and inflammatory responses. For example, CRP is an inflammatory marker, while insulin and glucose are central to carbohydrate metabolism, and cholesterol and triglycerides are key lipids. [12] Understanding the regulatory networks governing these biomolecules provides insight into how early life factors can predispose individuals to conditions like type 2 diabetes or cardiovascular disease, where disruptions in these pathways are central to disease pathogenesis.
Interplay of Genetics and Environment in Lifelong Health
The trajectory of an individual's health from birth through adulthood is a complex outcome of the intricate interplay between genetic predispositions and environmental factors. Genetic association analyses often account for potential gene-environment interactions, evaluating how the effects of specific genetic loci might be modified by early life conditions such as gestational age or birth BMI. [12] For example, while certain genes might predispose an individual to metabolic dysregulation, their expression and impact can be amplified or mitigated by factors like early growth patterns or subsequent weight gain. [4] This dynamic interaction contributes to the observed systemic consequences, where early life exposures and genetic variations collectively shape an individual's susceptibility to complex diseases, manifesting as altered metabolic traits and increased risk for conditions like cardiovascular disease and type 2 diabetes later in life. [12]
Genetic Regulation of Early Metabolic Programming
Genetic variants identified in birth cohorts play a fundamental role in shaping early metabolic trajectories, influencing an individual's predisposition to various health outcomes later in life. Genome-wide association studies (GWAS) have pinpointed specific loci associated with metabolic traits, demonstrating how genetic predispositions, such as those involving the fatty acid desaturase genes _FADS1_ and _FADS2_, or the melatonin receptor 1B gene _MTNR1B_, impact the foundational metabolic profile from birth. [1] These genetic influences underscore the significance of gene regulation in the developing system, where variations can alter the expression and function of proteins critical for metabolic processes.
Beyond broad metabolic traits, specific genetic regulatory mechanisms impact distinct developmental processes that have early-life origins. For instance, the _BCL11A_ gene, encoding a zinc-finger protein, acts as a nuclear repressor to regulate the production of fetal hemoglobin. [22] Variations in such transcription factors illustrate how precise gene regulation, even at the level of fetal development, can have lasting physiological consequences, thereby demonstrating the intricate interplay between genetic programming and early biological function.
Signaling and Energy Homeostasis Pathways
Receptor activation and subsequent intracellular signaling cascades are central to the regulation of energy metabolism and overall physiological homeostasis. Genes such as _ADIPOQ_, which encodes adiponectin, and _LEPR_, coding for the leptin receptor, are integral to these pathways, modulating insulin sensitivity, energy balance, and inflammatory responses. [26] Dysregulation in these signaling pathways can contribute to significant health issues, including insulin resistance, type 2 diabetes, and an increased risk for cardiovascular disease.
Furthermore, the activity of key metabolic enzymes and their regulatory proteins directly influences glucose and lipid metabolism. For example, the glucokinase regulatory protein (_GCKR_) plays a role in modulating glucokinase activity, impacting fasting serum triacylglycerol levels and insulinemia. [27] Similarly, variants in _HMGCR_, which encodes HMG-CoA reductase, a rate-limiting enzyme in cholesterol biosynthesis, are associated with low-density lipoprotein cholesterol levels. [28] These examples highlight how metabolic regulation and allosteric control of enzymes are critical components in maintaining metabolic health, and their dysregulation can lead to conditions like dyslipidemia and type 2 diabetes. [29]
Metabolite Transport and Flux Control
The precise transport of metabolites across cellular membranes is crucial for maintaining physiological balance and preventing accumulation or deficiency. _SLC2A9_, also known as _GLUT9_, is a facilitative glucose transporter family member with a significant role in the transport of urate and fructose. [30] Genetic variants within such transporters can directly alter the flux of these metabolites, affecting their serum concentrations and excretion rates, which are critical for systemic metabolic homeostasis. [30]
Regulatory mechanisms, including alternative splicing, can profoundly impact the function and trafficking of these transporters. For instance, alternative splicing of _GLUT9_ can alter its cellular localization and substrate selectivity, thereby modulating the efficiency of urate and fructose transport. [31] This form of post-translational regulation demonstrates how subtle molecular modifications can have significant consequences for metabolic flux, directly linking to disease-relevant mechanisms such as the development of hyperuricemia and gout.
Systems-Level Integration and Disease Mechanisms
Metabolic pathways are not isolated but form an intricate network, exhibiting extensive crosstalk and hierarchical regulation that collectively determine an organism's physiological state. Genome-wide association studies, particularly those integrating metabolomics, reveal that genetic variants often affect intermediate phenotypes, providing critical insights into these complex, interconnected pathways. [25] Studies on birth cohorts further emphasize this systems-level integration, demonstrating how early life growth trajectories and metabolic profiles can predict long-term health outcomes, including susceptibility to coronary events and alterations in serum lipid levels decades later. [1]
The dysregulation within these integrated pathways contributes to the development of complex metabolic diseases. For instance, dyslipidemia is often polygenic, involving common variants at numerous loci that collectively contribute to the emergent properties of the disease. [8] Understanding these network interactions and the compensatory mechanisms that arise from pathway dysregulation is crucial for identifying potential therapeutic targets and developing effective interventions. This is particularly relevant for conditions rooted in early life metabolic programming, where interventions could mitigate lifetime disease risk. [1]
Clinical Relevance
The circumstances and characteristics surrounding birth, including gestational age, birth weight, and early postnatal growth, serve as critical early life markers with profound implications for long-term health outcomes. Research from large birth cohort studies has elucidated the prognostic value of these factors, linking them to the development of chronic diseases and informing strategies for risk stratification and personalized prevention.
Early Life Markers and Long-term Health Prognosis
Characteristics at birth and during early development are significant prognostic indicators for health trajectories throughout the lifespan. Studies have demonstrated that early life factors can predict adult health conditions, such as blood pressure at age 31 years. [2] Furthermore, specific growth trajectories during childhood have been associated with the risk of coronary events in adulthood. [3] The interplay between size at birth, subsequent weight gain over the life course, and the presence of low-grade inflammation in young adulthood highlights a continuum of risk established early in life. [4] This early developmental patterning extends to metabolic health, with growth patterns before two years of age influencing serum lipid profiles up to 60 years later. [5] These findings underscore the critical role of birth parameters and early growth as predictive markers for future disease burden, particularly for cardiovascular and metabolic conditions.
Risk Stratification and Personalized Prevention
Understanding the long-term implications of early life factors enables effective risk stratification and the development of personalized prevention strategies. Identifying groups at risk, such as low birth weight infants, is crucial for mitigating adverse perinatal mortality outcomes and subsequent health complications. [6] Investigations into gene-environment interactions, particularly those involving gestational age, birth BMI, and early growth, provide insights into how genetic predispositions are modified by developmental factors. [1] This understanding allows for the identification of high-risk individuals who may benefit from targeted monitoring or early lifestyle interventions. By integrating information about birth characteristics with genetic data, healthcare providers can move towards more personalized medicine approaches, tailoring preventative measures to an individual's unique risk profile established from the very beginning of life.
Metabolic and Cardiovascular Comorbidities
Early life characteristics are strongly associated with a spectrum of metabolic and cardiovascular comorbidities later in life, highlighting overlapping phenotypes rooted in developmental origins. Fetal growth, for instance, has been identified as a key factor influencing the risk for both cardiovascular disease (CVD) and type 2 diabetes (T2D). [1] Beyond direct disease risk, associations extend to intermediate markers, such as the link between size at birth, weight gain, and systemic low-grade inflammation in young adulthood. [4] Moreover, early growth patterns are implicated in the long-term regulation of serum lipids and blood pressure, contributing to a broader syndromic presentation of metabolic dysregulation . [2], [5] These findings emphasize that interventions targeting early life factors could have broad benefits across multiple interconnected health conditions.
References
[1] Sabatti, C et al. "Genome-wide association analysis of metabolic traits in a birth cohort from a founder population." Nat Genet, vol. 41, no. 1, 2009, pp. 35-46.
[2] Jarvelin, M. R., et al. "Early life factors and blood pressure at age 31 years in the 1966 northern Finland birth cohort." Hypertension, vol. 44, no. 6, 2004, pp. 838-846.
[3] Barker, D. J., et al. "Trajectories of growth among children who have coronary events as adults." New England Journal of Medicine, vol. 353, no. 17, 2005, pp. 1802-1809.
[4] Tzoulaki, I et al. "Size at birth, weight gain over the life course, and low-grade inflammation in young adulthood: northern Finland 1966 Birth Cohort study." Eur Heart J, vol. 29, no. 8, 2008, pp. 1049-1056.
[5] Kajantie, E et al. "Growth before 2 years of age and serum lipids 60 years later: the Helsinki Birth Cohort study." Int J Epidemiol, vol. 37, no. 2, 2008, pp. 280-289.
[6] Rantakallio, P. "Groups at risk in low birth weight infants and perinatal mortality." Acta Paediatr Scand Suppl, vol. 193, 1969, p. 43.
[7] Vasan, R. S., et al. "Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study." BMC Med Genet, vol. 8, suppl. 1, 2007, S2.
[8] Kathiresan, S., et al. "Common variants at 30 loci contribute to polygenic dyslipidemia." Nat Genet, vol. 40, no. 12, 2008, pp. 1421-31.
[9] Willer, C. J., et al. "Newly identified loci that influence lipid concentrations and risk of coronary artery disease." Nat Genet, vol. 40, no. 2, 2008, pp. 161–169.
[10] Benyamin, B., et al. "Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels." Am J Hum Genet, vol. 84, no. 1, 2009, pp. 60–65.
[11] Dehghan, A., et al. "Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study." Lancet, vol. 372, no. 9654, 2008, pp. 1953–1961.
[12] Sabatti, C. "Genome-wide association analysis of metabolic traits in a birth cohort from a founder population." Nat Genet (2008).
[13] Benjamin, Emelia J et al. "Genome-wide association with select biomarker traits in the Framingham Heart Study." BMC Medical Genetics, vol. 8, no. Suppl 1, 2007, pp. S11.
[14] Hwang, Shih-Jen et al. "A genome-wide association for kidney function and endocrine-related traits in the NHLBI's Framingham Heart Study." BMC Medical Genetics, vol. 8, no. Suppl 1, 2007, pp. S10.
[15] O'Donnell, C. J., et al. "Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI's Framingham Heart Study." BMC Med Genet, vol. 8, suppl. 1, 2007, S11.
[16] Wilk, J Bradford et al. "Framingham Heart Study genome-wide association: results for pulmonary function measures." BMC Medical Genetics, vol. 8, no. Suppl 1, 2007, pp. S13.
[17] Chambers, J. C., et al. "Common genetic variation near MC4R is associated with waist circumference and insulin resistance." Nat Genet, vol. 40, no. 6, 2008, pp. 712–714.
[18] Pan, L., C. Ober, and M. Abney. "Heritability estimation of sex-specific effects on human quantitative traits." Genet Epidemiol, vol. 31, no. 4, 2007, pp. 338–347.
[19] Service, S., et al. "Magnitude and distribution of linkage disequilibrium in population isolates and implications for genome-wide association studies." Nat. Genet., vol. 38, no. 5, 2006, pp. 556–560.
[20] Varilo, T., and L. Peltonen. "Isolates and their potential use in complex gene mapping efforts." Curr. Opin. Genet. Dev., vol. 14, no. 3, 2004, pp. 316–323.
[21] Ober, C., M. Abney, and M. S. McPeek. "The genetic dissection of complex traits in a founder population." Am J Hum Genet, vol. 69, no. 5, 2001, pp. 1068–1079.
[22] Menzel, S., et al. "A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15." Nat Genet, vol. 39, no. 9, 2007, pp. 1197-9.
[23] Uda, M., et al. "Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia." Proc Natl Acad Sci U S A, vol. 105, no. 5, 2008, pp. 1620–1625.
[24] Aulchenko, Y. S., et al. "Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts." Nat Genet, vol. 40, no. 11, 2008, pp. 1315–1320.
[25] Gieger, C., et al. "Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum." PLoS Genet, vol. 4, no. 11, 2008, e1000282.
[26] Ling, H., et al. "Genome-wide linkage and association analyses to identify genes influencing adiponectin levels: the GEMS Study." Obesity (Silver Spring), vol. 17, no. 3, 2009, pp. 471-7.
[27] Ridker, P. M., et al. "Loci related to metabolic-syndrome pathways including _LEPR_, _HNF1A_, _IL6R_, and _GCKR_ associate with plasma C-reactive protein: the Women's Genome Health Study." Am J Hum Genet, vol. 82, no. 5, 2008, pp. 1185-92.
[28] Burkhardt, R., et al. "Common SNPs in _HMGCR_ in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13." Arterioscler Thromb Vasc Biol, 2008.
[29] Saxena, R., et al. "Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels." Science, vol. 316, no. 5829, 2007, pp. 1331-6.
[30] Vitart, V., et al. "_SLC2A9_ is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout." Nat Genet, vol. 40, no. 4, 2008, pp. 432-6.
[31] McArdle, P. F., et al. "Association of a common nonsynonymous variant in _GLUT9_ with serum uric acid levels in old order amish." Arthritis Rheum, vol. 58, no. 10, 2008, pp. 3270-8.